Quest Diagnostics (DGX) has shared promising Q3 2025 financial results and adjusted its full-year guidance, contributing to strong momentum in the market. Many financial institutions, including Barclays and Truist Financial, maintained their current ratings and price targets for the stock, while Leerink Partners and Jefferies increased their price targets. The company's successful earnings reports superseded financial projections, compelling analysts to re-evaluate Quest's long-term growth potential. Strategic growth moves were also highlighted including a joint venture with Corewell Health for enhanced laboratory services in Michigan and a historic collaboration with Epic to improve patient laboratory testing experiences. Quest Diagnostic's healthcare innovation includes precision trading, the introduction of technologically advanced pharmacogenomics testing, efforts to improve the lab testing experience, and preparation to offer FDA-cleared Fujirebio blood tests for Alzheimer's disease. Fentanyl positivity rose by seven times in random tests compared to pre-employment drug screens, according to their 2025 drug testing index. Despite a strong revenue traction, there are concerns about the company's efficiency, which might alter their long-term profit outlook. Moreover, DGX stock also reached an all-time high at 191.87 USD.
Quest Diagnostics DGX News Analytics from Thu, 30 Jan 2025 08:00:00 GMT to Sat, 25 Oct 2025 02:11:50 GMT - Rating 8 - Innovation 7 - Information 9 - Rumor 1
